New drug xaluritamig takes on tough ewing sarcoma in early trial

NCT ID NCT07297979

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-phase trial is testing a drug called xaluritamig (AMG 509) in 50 adults, adolescents, and children with Ewing sarcoma that has relapsed or not responded to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look for any signs that it is fighting the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: xaluritamig (AMG 509), a drug given by IV infusion
What this could lead to: If it works, this could point toward a new treatment option for people with Ewing sarcoma that has come back or not responded to standard therapy.
What could go wrong: This is a very early (phase 1b) and small trial (50 people), so it may not show enough benefit or could have side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cedars Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Chris OBrien Lifehouse
RECRUITING

Camperdown, New South Wales, 2050, Australia
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Perth Childrens Hospital
RECRUITING

Nedlands, Western Australia, 6009, Australia
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
University of California Los Angeles
RECRUITING

Los Angeles, California, 90995-1752, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.